A new molecule developed by researchers at Oregon Health & Science University offers a promising avenue to treat intractable cases of triple-negative breast cancer—a form of cancer that is notoriously aggressive and lacks effective treatments.

In a study published today in the journal Cell Reports Medicine, researchers describe the effect of a molecule known as SU212 to inhibit an enzyme that is critical to cancer progression. The research was conducted in a humanized mouse model.

“It’s an important step forward to treat triple-negative breast cancer,” said senior author Sanjay V. Malhotra, Ph.D., co-director of the Center for Experimental Therapeutics in the OHSU Knight Cancer Institute. “Triple-negative breast cancer is an aggressive form of cancer and there are no effective drugs available right now.”